Join Dr. Kirk Campbell (University of Pennsylvania) and Dr. Alessia Fornoni (University of Miami) for an in-depth conversation on the evolving landscape of Focal Segmental Glomerulosclerosis (FSGS).

The first episode of this three-part FSGS series explores the transition from traditional histological classifications to a more precise clinical and molecular understanding of the disease. Dr. Campbell and Dr. Fornoni discuss the definition and pathogenesis of FSGS as well as clinical management and the future of treatment. 

In this episode of KDIGO Conversations in Nephrology, Dr. Kirk Campbell speaks with Dr. Alessia Fornoni about the evolving understanding of focal segmental glomerulosclerosis (FSGS) as a podocytopathy driven by podocyte injury. The discussion explores advances in FSGS classification, the role of angiotensin II and endothelin-1 signaling in disease progression, emerging insights into disease mechanisms, and how new targeted therapies may help preserve podocyte function and slow the progression of kidney disease.

This episode is part of a special three-part KDIGO Conversations in Nephrology series exploring advances in podocyte biology, disease mechanisms, emerging therapies, and the evolving clinical management of FSGS.